Welcure Medication & Prescribed drugs Ltd (BSE: 524661) within the board of administrators assembly held on August 22 has thought of and authorised a bonus and inventory cut up. Following the corporate’s stellar Q1FY26 monetary outcomes, this transfer is geared toward enhancing liquidity and broadening shareholding.
Highlights:
|
1:10 Bonus Subject
The Board has thought of and authorised the problem of bonus shares within the ratio of 1:10 (one bonus fairness share of Rs 10 every for each 10 fairness shares of Rs 10 every) to the eligible fairness shareholders of the corporate as on the proposed document date by capitalization of securities premium, topic to the approval of the shareholders of the corporate. A complete of 1,12,35,820 fairness shares will likely be issued as bonus shares. The bonus shares can be credited inside two months of the date of the board approval.
As of June 30, 2025, the corporate has free reserves amounting to Rs 13.37 crore. Submit-bonus subject paid-up share capital: 12,35,94,020 fairness shares of face worth of Rs 10 every aggregating to share capital of Rs 123.59 crore. The issuance of bonus shares will likely be carried out of the securities premium acquired in money and/or free reserve and/or retained earnings of the corporate, topic to the approval of the shareholders.
10:1 Inventory Cut up
The board of administrators additionally thought of and authorised a ten:1 inventory cut up. One fairness share of the face worth of Rs 10 every will likely be subdivided/cut up into 10 fairness shares of the face worth of Re 1 every, topic to the approval of fairness shareholders of the corporate by postal poll.
The inventory cut up is geared toward enhancing the liquidity of the corporate’s shares out there and making them extra accessible to retail traders. The document date for the sub-division/cut up of current fairness shares shall be determined after taking the aforesaid approval of the fairness shareholders of the corporate. The inventory cut up is predicted to be accomplished inside two months.
Improve Authorised Share Capital
The board additionally thought of and authorised the rise within the authorised share capital of the corporate from Rs 186 crore to Rs 196 crore within the board assembly on August 22, which is topic to the approval of the members.
Welcure Medication & Prescribed drugs Ltd to arrange a state-of-the-art agro pharma analysis laboratory; it can make investments Rs. 70-80 crore within the undertaking Welcure Medication & Prescribed drugs Ltd (BSE: 524661) is planning to speculate round Rs. 70-80 crore in establishing a state-of-the-art cGMP normal analysis laboratory devoted to agro-pharma analysis. The scale of the undertaking is estimated to be round Rs. 70-80 crore, together with laboratory infrastructure, pilot strains, analytics and high quality programs. The amenities and processes will likely be designed to align with relevant cGMP requirements and the US FDA’s botanical drug growth steerage (as related), to be able to allow participation in broader worldwide markets for botanical/ayurvedic merchandise, topic to all essential approvals. The proposed web site, timeline and commissioning plan will likely be finalised put up approvals. The corporate proposes to boost as much as Rs. 80 crore by the use of Certified Institutional Placement (QIP), in a number of tranches, to fund the agro-pharma analysis laboratory and for basic company functions. The assembly of the board of administrators will likely be held on August 28, 2025, to contemplate and, if deemed applicable, approve the aforesaid fund-raising by QIP, together with approving enabling resolutions, subject construction and looking for shareholders’ approval as could also be required. The target of the laboratory will likely be to analysis, validate and scale processes for the conversion of agricultural/botanical inputs into pharma-grade merchandise geared toward public well being and societal wellbeing. The above proposals are topic to requisite Board, shareholder, regulatory and statutory approvals and market circumstances. The corporate is planning to speculate round Rs. 70-80 crore in establishing a state-of-the-art cGMP normal analysis laboratory devoted to agro-pharma analysis, together with laboratory infrastructure, pilot strains, analytics & high quality programs.
|
These proposals are a part of Welcure’s dedication to enhancing market liquidity, increasing retail participation, and bettering affordability for traders. These proposals are topic to the board’s determination and subsequent statutory/shareholder approvals. If authorised, the corporate will announce document dates and implementation timelines individually, in accordance with SEBI Itemizing Obligations and Disclosure Necessities (LODR) and relevant legal guidelines.
Talking on this growth, the corporate administration commented, “As part of our evolving enterprise methods, we’ve give you this proposal for Inventory Cut up and Bonus Subject. These proposals replicate our confidence in Welcure’s progress trajectory and our dedication to enhancing shareholder worth. Coupled with our robust monetary outcomes and asset-light enterprise mannequin, these steps goal to make Welcure’s shares extra accessible and liquid out there.”
Glorious Q1FY26 Outcomes –
Lately, the corporate introduced its Q1FY26 monetary outcomes. Pushed by its strategic foray into fee-based export-oriented sourcing companies, the corporate’s income from operations rose sharply to Rs. 299.91 crore in Q1FY26, up from Rs. 21.21 crore in Q4FY25. This represents progress of round 1300% QoQ. Internet Revenue surged to Rs. 23.29 crore from Rs. 2.50 crore in Q4FY25, marking an 830% enhance.
Beforehand, the corporate accomplished seven export-sourcing assignments totalling Rs. 299.91 crore, incomes fastened fee revenue with no stock or logistics publicity, sustaining its debt-free standing. As well as, a Rs. 517 crore world sourcing mandate from Thailand-based Fortune Sagar Impex Firm Restricted is predicted to generate roughly Rs. 25.85 crore in service revenue throughout FY26.
About Welcure Medication & Prescribed drugs Ltd:
Included in 1992, Welcure Medication & Prescribed drugs Ltd is a longtime pharmaceutical firm in India, engaged within the manufacture and commerce of a variety of healthcare formulations. With a give attention to high quality, compliance, and world integration, Welcure continues to increase its presence in each home and worldwide markets.
This text is from the Model Desk. Consumer discretion is suggested.
